Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers

James R Brasic, Yun Zhou, John L. Musachio, John Hilton, Hong Fan, Andrew Crabb, Christopher J. Endres, Melvin J. Reinhardt, Ahmet S. Dogan, Mohab Alexander, Olivier Rousset, Marika A. Maris, Jeffrey Galecki, Ayon Nandi, Dean Foster Wong

Research output: Contribution to journalArticle

Abstract

(S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-[ 123I]IA), a novel potent radioligand for high-affinity α4β2* neuronal nicotinic acetylcholine receptors (nAChRs), provides a means to evaluate the density and the distribution of nAChRs in the living human brain. We sought in healthy adult smokers and nonsmokers to (1) evaluate the safety, tolerability, and efficacy of 5-[123I]IA in an open nonblind trial and (2) to estimate the density and the distribution of α4β2* nAChRs in the brain. Single photon emission computed tomography (SPECT) was performed for 5 h after the i.v. administration of ∼0.001 lg/kg (∼10 mCi) 5-[123I]IA. Blood pressure, heart rate, and neurobehavioral status were monitored before, during, and after the administration of 5-[123I]IA to 12 healthy adults (8 men and 4 women) (6 smokers and 6 nonsmokers) ranging in age from 19 to 46 years (mean = 28.25, standard deviation = 8.20). High plasma-nicotine level was significantly associated with low 5-[123I]IA binding in: (1) the caudate head, the cerebellum, the cortex, and the putamen, utilizing both the Sign and Mann-Whitney U-tests; (2) the fusiform gyrus, the hippocampus, the parahippocampus, and the pons utilizing the Mann-Whitney U-test; and (3) the thalamus utilizing the Sign test. We conclude that 5-[123I]IA is a safe, well-tolerated, and effective pharmacologic agent for human subjects to estimate high-affinity α4/β2 nAChRs in the living human brain.

Original languageEnglish (US)
Pages (from-to)339-358
Number of pages20
JournalSynapse
Volume63
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Nicotinic Receptors
Single-Photon Emission-Computed Tomography
Brain
Nonparametric Statistics
Parahippocampal Gyrus
Pons
Putamen
Temporal Lobe
Thalamus
Nicotine
Cerebellum
Heart Rate
Head
Blood Pressure
Safety
5-iodo-3-(2-azetidinylmethoxy)pyridine

Keywords

  • Binding
  • Density
  • Distribution
  • Infusions
  • Safety
  • Tomography
  • Treatment efficacy

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. / Brasic, James R; Zhou, Yun; Musachio, John L.; Hilton, John; Fan, Hong; Crabb, Andrew; Endres, Christopher J.; Reinhardt, Melvin J.; Dogan, Ahmet S.; Alexander, Mohab; Rousset, Olivier; Maris, Marika A.; Galecki, Jeffrey; Nandi, Ayon; Wong, Dean Foster.

In: Synapse, Vol. 63, No. 4, 04.2009, p. 339-358.

Research output: Contribution to journalArticle

Brasic, JR, Zhou, Y, Musachio, JL, Hilton, J, Fan, H, Crabb, A, Endres, CJ, Reinhardt, MJ, Dogan, AS, Alexander, M, Rousset, O, Maris, MA, Galecki, J, Nandi, A & Wong, DF 2009, 'Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers', Synapse, vol. 63, no. 4, pp. 339-358. https://doi.org/10.1002/syn.20611
Brasic, James R ; Zhou, Yun ; Musachio, John L. ; Hilton, John ; Fan, Hong ; Crabb, Andrew ; Endres, Christopher J. ; Reinhardt, Melvin J. ; Dogan, Ahmet S. ; Alexander, Mohab ; Rousset, Olivier ; Maris, Marika A. ; Galecki, Jeffrey ; Nandi, Ayon ; Wong, Dean Foster. / Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. In: Synapse. 2009 ; Vol. 63, No. 4. pp. 339-358.
@article{ee1438fcb3e54e52b1a4f36ddabdb04e,
title = "Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers",
abstract = "(S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-[ 123I]IA), a novel potent radioligand for high-affinity α4β2* neuronal nicotinic acetylcholine receptors (nAChRs), provides a means to evaluate the density and the distribution of nAChRs in the living human brain. We sought in healthy adult smokers and nonsmokers to (1) evaluate the safety, tolerability, and efficacy of 5-[123I]IA in an open nonblind trial and (2) to estimate the density and the distribution of α4β2* nAChRs in the brain. Single photon emission computed tomography (SPECT) was performed for 5 h after the i.v. administration of ∼0.001 lg/kg (∼10 mCi) 5-[123I]IA. Blood pressure, heart rate, and neurobehavioral status were monitored before, during, and after the administration of 5-[123I]IA to 12 healthy adults (8 men and 4 women) (6 smokers and 6 nonsmokers) ranging in age from 19 to 46 years (mean = 28.25, standard deviation = 8.20). High plasma-nicotine level was significantly associated with low 5-[123I]IA binding in: (1) the caudate head, the cerebellum, the cortex, and the putamen, utilizing both the Sign and Mann-Whitney U-tests; (2) the fusiform gyrus, the hippocampus, the parahippocampus, and the pons utilizing the Mann-Whitney U-test; and (3) the thalamus utilizing the Sign test. We conclude that 5-[123I]IA is a safe, well-tolerated, and effective pharmacologic agent for human subjects to estimate high-affinity α4/β2 nAChRs in the living human brain.",
keywords = "Binding, Density, Distribution, Infusions, Safety, Tomography, Treatment efficacy",
author = "Brasic, {James R} and Yun Zhou and Musachio, {John L.} and John Hilton and Hong Fan and Andrew Crabb and Endres, {Christopher J.} and Reinhardt, {Melvin J.} and Dogan, {Ahmet S.} and Mohab Alexander and Olivier Rousset and Maris, {Marika A.} and Jeffrey Galecki and Ayon Nandi and Wong, {Dean Foster}",
year = "2009",
month = "4",
doi = "10.1002/syn.20611",
language = "English (US)",
volume = "63",
pages = "339--358",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Single photon emission computed tomography experience with (S)-5-[ 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers

AU - Brasic, James R

AU - Zhou, Yun

AU - Musachio, John L.

AU - Hilton, John

AU - Fan, Hong

AU - Crabb, Andrew

AU - Endres, Christopher J.

AU - Reinhardt, Melvin J.

AU - Dogan, Ahmet S.

AU - Alexander, Mohab

AU - Rousset, Olivier

AU - Maris, Marika A.

AU - Galecki, Jeffrey

AU - Nandi, Ayon

AU - Wong, Dean Foster

PY - 2009/4

Y1 - 2009/4

N2 - (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-[ 123I]IA), a novel potent radioligand for high-affinity α4β2* neuronal nicotinic acetylcholine receptors (nAChRs), provides a means to evaluate the density and the distribution of nAChRs in the living human brain. We sought in healthy adult smokers and nonsmokers to (1) evaluate the safety, tolerability, and efficacy of 5-[123I]IA in an open nonblind trial and (2) to estimate the density and the distribution of α4β2* nAChRs in the brain. Single photon emission computed tomography (SPECT) was performed for 5 h after the i.v. administration of ∼0.001 lg/kg (∼10 mCi) 5-[123I]IA. Blood pressure, heart rate, and neurobehavioral status were monitored before, during, and after the administration of 5-[123I]IA to 12 healthy adults (8 men and 4 women) (6 smokers and 6 nonsmokers) ranging in age from 19 to 46 years (mean = 28.25, standard deviation = 8.20). High plasma-nicotine level was significantly associated with low 5-[123I]IA binding in: (1) the caudate head, the cerebellum, the cortex, and the putamen, utilizing both the Sign and Mann-Whitney U-tests; (2) the fusiform gyrus, the hippocampus, the parahippocampus, and the pons utilizing the Mann-Whitney U-test; and (3) the thalamus utilizing the Sign test. We conclude that 5-[123I]IA is a safe, well-tolerated, and effective pharmacologic agent for human subjects to estimate high-affinity α4/β2 nAChRs in the living human brain.

AB - (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-[ 123I]IA), a novel potent radioligand for high-affinity α4β2* neuronal nicotinic acetylcholine receptors (nAChRs), provides a means to evaluate the density and the distribution of nAChRs in the living human brain. We sought in healthy adult smokers and nonsmokers to (1) evaluate the safety, tolerability, and efficacy of 5-[123I]IA in an open nonblind trial and (2) to estimate the density and the distribution of α4β2* nAChRs in the brain. Single photon emission computed tomography (SPECT) was performed for 5 h after the i.v. administration of ∼0.001 lg/kg (∼10 mCi) 5-[123I]IA. Blood pressure, heart rate, and neurobehavioral status were monitored before, during, and after the administration of 5-[123I]IA to 12 healthy adults (8 men and 4 women) (6 smokers and 6 nonsmokers) ranging in age from 19 to 46 years (mean = 28.25, standard deviation = 8.20). High plasma-nicotine level was significantly associated with low 5-[123I]IA binding in: (1) the caudate head, the cerebellum, the cortex, and the putamen, utilizing both the Sign and Mann-Whitney U-tests; (2) the fusiform gyrus, the hippocampus, the parahippocampus, and the pons utilizing the Mann-Whitney U-test; and (3) the thalamus utilizing the Sign test. We conclude that 5-[123I]IA is a safe, well-tolerated, and effective pharmacologic agent for human subjects to estimate high-affinity α4/β2 nAChRs in the living human brain.

KW - Binding

KW - Density

KW - Distribution

KW - Infusions

KW - Safety

KW - Tomography

KW - Treatment efficacy

UR - http://www.scopus.com/inward/record.url?scp=63049095919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049095919&partnerID=8YFLogxK

U2 - 10.1002/syn.20611

DO - 10.1002/syn.20611

M3 - Article

C2 - 19140167

AN - SCOPUS:63049095919

VL - 63

SP - 339

EP - 358

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 4

ER -